A Way to Increase the Bioaccesibility and Photostability of Roflumilast, a COPD Treatment, by Cyclodextrin Monomers

Roflumilast is an orally available inhibitor of phosphodiesterase (PDE) type 4, which is widely used in chronic obstructive pulmonary diseases. However, it has low solubility and adverse effects include diarrhea and nausea. Since its solubilization may improve treatment and, dismissing any adverse e...

Descripción completa

Detalles Bibliográficos
Autores principales: Matencio, Adrián, Hernández-García, Samanta, García-Carmona, Francisco, López-Nicolás, José Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6571910/
https://www.ncbi.nlm.nih.gov/pubmed/31060253
http://dx.doi.org/10.3390/polym11050801

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6571910/
https://www.ncbi.nlm.nih.gov/pubmed/31060253
http://dx.doi.org/10.3390/polym11050801

Ejemplares similares